Contact

All Publications

  • Electroretinographic findings in retinal vasculitis. The British journal of ophthalmology Ghoraba, H. H., Matsumiya, W., Or, C., Khojasteh, H., Patel, P., Karaca, I., Regenold, J., Zaidi, M., Hwang, J., Lajevardi, S., Yavari, N., Than, N. T., Park, S. W., Akhavanrezayat, A., Uludag, G., Yasar, C., Leung, L. B., Nguyen, Q. D. 2022

    Abstract

    To describe and correlate electroretinographic responses with clinical and angiographic findings in retinal vasculitis (RV).Medical records of patients with diagnosis of RV at a tertiary eye centre from December 2017 to May 2021 were reviewed. Cases in which fluorescein angiography (FFA) and full field electroretinography (ffERG) were done within 1 month were included. FFAs were graded according to the Angiography Scoring for Uveitis Working Group from 0 to 40, where 0 is normal. A novel ffERG grading system was implemented where individual waves were graded for timing and amplitude and general ffERG score was determined with 6 being a perfect score.20 patients (34 eyes) were included. Mean age was 43.9±19.8 years; 70% were female. Median best-corrected visual acuity was 0.8 (0.08-1). Mean FFA score was 12.6±6.5. Median general ffERG score was 5 (0-6). 68% and 91% of eyes had responses with general ffERG scores ≥5 and 4, respectively. Flicker timing was most commonly affected.FFA scores weakly correlated with delayed photopic cone b-wave and flicker timing (p=0.03 and 0.016, respectively). Vitreous haze moderately correlated with delayed cone b-wave timing (p<0.001), delayed flicker timing (p=0.002) and weakly correlated with lower flicker amplitude (p=0.03). Underlying systemic disease was associated with poor ffERG responses.In this study, RV was not frequently associated with severe global retinal dysfunction Higher FFA scores, and vitreous haze grading were weakly, but significantly, correlated with cone-generated ffERG responses.

    View details for DOI 10.1136/bjo-2022-321716

    View details for PubMedID 36130816

  • C3 glomerulopathy associated with both hypertensive retinopathy and purtscher-like retinopathy. American journal of ophthalmology case reports Zaidi, M., Mishra, K., Nguyen, H. V., Miller, P. P., Ghoraba, H., Karaca, I., Matsumiya, W., Nguyen, Q. D., Leung, L. B. 2022; 27: 101683

    Abstract

    Purpose: This article reports the case of a 21-year-old woman with both hypertensive retinopathy and Purtscher-like retinopathy in association with C3 glomerulopathy.Observations: The patient was referred for bilateral painless vision loss with posterior pole cotton wool spots, optic disc edema, and confluent retinal whitening suggesting a mixed picture of hypertensive retinopathy, with initial blood pressure 236/152, and Purtscher-like retinopathy. She was subsequently diagnosed with C3 glomerulopathy which likely caused her severe hypertension and which likely occurred alongside Purtscher-like retinopathy due to a shared pathogenesis of complement dysregulation. Follow up examination and imaging revealed gradual improvement in visual acuity, almost complete resolution of fundus exam abnormalities, improvement in macular nonperfusion, resolution of disc leakage and choroidal leakage, resolution of macular edema, and residual outer retinal hyperreflective foci in both eyes.Conclusion and importance: This case represents the first report of both Purtscher-like retinopathy and hypertensive retinopathy occurring in association with C3 glomerulopathy. It supports investigation of anti-complement therapy as a potential treatment for Purtscher-like retinopathy.

    View details for DOI 10.1016/j.ajoc.2022.101683

    View details for PubMedID 36016724

  • Posterior manifestations and longitudinal outcomes in TINU syndrome Uludag, G., Hassan, M., Regenold, J., Akhavanrezayat, A., Mobasserian, A., Yasar, C., Or, C., Khojasteh, H., Ghoraba, H., Karaca, I., Zaidi, M., Yavari, N., Than, N., Park, S., Bazojoo, V., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844437002261

  • Electroretinographic findings in retinal vasculitis Ghoraba, H., Matsumiya, W., Patel, P., Or, C., Karaca, I., Regenold, J., Zaidi, M., Khojasteh, H., Hwang, J., Lajevardi, S., Yavari, N., Park, S., Akhavanrezayat, A., Mobasserian, A., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844401302086

  • Efficacy of infliximab and tocilizumab in non-infectious retinal vasculitis: 12-month outcomes Karaca, I., Ghoraba, H., Hwang, J., Or, C., Matsumiya, W., Uludag, G., Zaidi, M., Regenold, J., Khojasteh, H., Mobasserian, A., Park, S., Than, N., Yavari, N., Bazojoo, V., Do, D. V., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844437002245

  • Correlation between Diopsys (R) NOVA fixed-luminance flicker phase and Diagnosys (R) flicker implicit time Regenold, J., Ghoraba, H., Hien Luong Doan, Zaidi, M., Hwang, J., Or, C., Karaca, I., Akhavanrezayat, A., Ngoc Than, Yasar, C., Yavari, N., Park, S., Khan, Y., Mobasserian, A., Do, D. V., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844401302077

  • Multifocal electroretinographic findings in eyes with posterior uveitis and angiographic macular leakage Hwang, J., Karaca, I., Lajevardi, S., Or, C., Zaidi, M., Regenold, J., Halim, M., Uludag, G., Yasar, C., Bazojoo, V., Than, N., Mobasserian, A., Sepah, Y. J., Khojasteh, H., Nguyen, Q., Ghoraba, H. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844401302088

  • Effect of Topical Bromfenac on Macular Thickness Changes after Vitrectomy or Phacovitrectomy for Epiretinal Membrane Park, S., Byon, I., Zaidi, M., Regenold, J., Uludag, G., Akhavanrezayat, A., Mobasserian, A., Or, C., Yasar, C., Ghoraba, H., Than, N., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844437002267

  • Repeatability of electroretinogram measurements Or, C., Ghoraba, H., Zaidi, M., Akhavanrezayat, A., Regenold, J., Uludag, G., Yasar, C., Park, S., Than, N., Hwang, J., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844401302074

  • Flicker ERG findings in posterior uveitis Than, N., Doan, H., Pham, B., Hwang, J., Regenold, J., Zaidi, M., Khan, Y., Matsumiya, W., Park, S., Ghoraba, H., Or, C., Uludag, G., Mobasserian, A., Akhavanrezayat, A., Do, D. V., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844401301053

  • Optical coherence tomography angiography and microperimetric findings in non-paraneoplastic autoimmune retinopathy Mobasserian, A., Ghoraba, H., Regenold, J., Or, C., Park, S., Karaca, I., Ngoc Than, Hwang, J., Uludag, G., Yavari, N., Matsumiya, W., Zaidi, M., Akhavanrezayat, A., Khojasteh, H., Hassan, M., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

    View details for Web of Science ID 000844437001284

  • Modeling absolute zone size in retinopathy of prematurity in relation to axial length. Scientific reports Wang, S. K., Korot, E., Zaidi, M., Ji, M. H., Al-Moujahed, A., Callaway, N. F., Kumm, J., Moshfeghi, D. M. 2022; 12 (1): 4717

    Abstract

    Treatment outcomes in retinopathy of prematurity (ROP) are closely correlated with the location (i.e. zone) of disease, with more posterior zones having poorer outcomes. The most posterior zone, Zone I, is defined as a circle centered on the optic nerve with radius twice the distance from nerve to fovea, or subtending an angle of 30 degrees. Because the eye enlarges and undergoes refractive changes during the period of ROP screening, the absolute area of Zone I according to these definitions may likewise change. It is possible that these differences may confound accurate assessment of risk in patients with ROP. In this study, we estimated the area of Zone I in relation to different ocular parameters to determine how variability in the size and refractive power of the eye may affect zoning. Using Gaussian optics, a model was constructed to calculate the absolute area of Zone I as a function of corneal power, anterior chamber depth, lens power, lens thickness, and axial length (AL), with Zone I defined as a circle with radius set by a 30-degree visual angle. Our model predicted Zone I area to be most sensitive to changes in AL; for example, an increase of AL from 14.20 to 16.58mm at postmenstrual age 32weeks was calculated to expand the area of Zone I by up to 72%. These findings motivate several hypotheses which upon future testing may help optimize treatment decisions for ROP.

    View details for DOI 10.1038/s41598-022-08680-5

    View details for PubMedID 35304549

  • Telemedicine screening for syphilitic chorioretinitis in the SUNDROP cohort. Eye (London, England) Zaidi, M. H., Rosenblatt, T. R., Al-Moujahed, A., Vail, D., Callaway, N. F., Nguyen, Q. D., Moshfeghi, D. M. 2022

    View details for DOI 10.1038/s41433-022-01967-x

    View details for PubMedID 35217825

  • Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses. Clinical ophthalmology (Auckland, N.Z.) Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., Mobasserian, A., DongChau, A. T., Or, C., Yasar, C., Mishra, K., Do, D., Nguyen, Q. D. 2022; 16: 1753-1771

    Abstract

    Gene therapy has emerged as a research topic of choice in recent years. The eye in particular is one of few organs of the body for which gene therapy has received Food and Drug Administration approval, and it remains a field of great interest for gene therapy development. However, its associated immune and inflammatory reactions may render the treatment ineffective or harmful, which are of particular concern for the eyes due to their susceptibility to inflammation. The severity of immune and inflammatory reactions depends on the choice of vector and its route of administration. Furthermore, most preclinical and clinical studies have shown that the dose of vectors is correlated with the degree of humoral response and ocular inflammation. The route of administration directly impacts the degree of immune and inflammatory reaction. Subretinal delivery produces a weaker humoral response than the intravitreal route. However, some studies have demonstrated that the subretinal delivery induces a stronger inflammatory reaction. On the other hand, several instances of vision loss due to severe late onset intraocular inflammation were reported in a clinical trial involving intravitreal delivery of viral vectors. When compared with the intravitreal route, suprachoroidal gene delivery has been shown to produce weaker humoral response. However, unlike the subretinal space, the suprachoroidal space is not known to have immune privilege status. Inflammatory reactions following ocular gene therapy are typically mild and most clinical and preclinical studies have shown that they can be controlled with topical, local or systemic steroids. However, severe inflammatory responses may occur and require aggressive management to avoid permanent vision loss. Further investigations are required to elucidate and expand our knowledge of inflammatory reactions, and their optimal management, following ocular gene therapy.

    View details for DOI 10.2147/OPTH.S364200

    View details for PubMedID 35685379

  • Unilateral acute anterior uveitis with macular edema following the use of sildenafil citrate in a patient with HLA-B27 positivity. American journal of ophthalmology case reports Regenold, J., Ghoraba, H., Akhavanrezayat, A., Matsumiya, W., Mobasserian, A., Karaca, I., Zaidi, M., Pham, B., Nguyen, Q. D. 2021; 24: 101228

    Abstract

    Purpose: To present a case of acute anterior uveitis with macular edema associated with sildenafil citrate use in an HLA-B27 positive patient.Observations: A 54-year-old Caucasian male presented at an ophthalmology tertiary center with complaint of pinkish discoloration, irritation, and photophobia in the left eye (OS). He noted that these symptoms appeared one day after using sildenafil for the first time to treat his erectile dysfunction. The patient had no significant ocular history besides refractive surgery in both eyes (OU) and his medical history was insignificant. Best-corrected visual acuity (BCVA) was 20/20 in the right eye (OD) and 20/25 in OS. Slit-lamp-examination (SLE) demonstrated trace cells and 1+ flare in the anterior chamber (AC) in OS and was nonrevealing in AC in OD. Spectral domain optical coherence tomography (SD-OCT) showed parafoveal subretinal hyperreflective deposits in OU. The patient was diagnosed with acute anterior uveitis (AAU) in the left eye and was placed on topical prednisolone acetate.At 2-week follow-up, the patient reported that his eye symptoms had improved since starting topical steroids but worsened again two days after he had used sildenafil for a second time. In OS, best-corrected visual acuity (BCVA) worsened to 20/40, and SLE revealed 1+ cells and 1+ flare in AC. SD-OCT revealed cystoid macular edema only in OS. Fluorescein angiography showed mild staining around the optic disc and significant macular leakage in OS and minimal macular leakage in OD. Uveitis evaluations revealed that the patient was human leukocyte antigen-27 (HLA-B27) positive. The patient was asked to remain off sildenafil and continue topical prednisolone acetate. At 3-month follow-up, BCVA improved to 20/20 in OS with no evidence of active inflammation.Conclusions and importance: Sildenafil citrate use might be associated with new onset of intraocular inflammation in predisposed patients. Further studies are necessary to establish this relationship.

    View details for DOI 10.1016/j.ajoc.2021.101228

    View details for PubMedID 34761138

  • Inferring retinal ganglion cell light response properties from intrinsic electrical feature Zaidi, M., Aggarwal, G., Shah, N. P., Karniol-Tambour, O., Goetz, G., Madugula, S., Gogliettino, A. R., Wu, E. G., Kling, A., Brackbill, N., Sher, A., Litke, A. M., Chichilnisky, E. J. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2021

    View details for Web of Science ID 000690761600407